- Crypto Price Analysis, BTC, XRP, AVAX, SOL and ALGO, Nov. 10: Bitcoin Rebounds, XRP RSI Falls Below 30, Solana Holds Its Bollinger Band as...
- Why Is Pi Network Price Up by 10% Today?
- XRP FUD Wave Intensifies as Questions Grow Over Who Is Amplifying It
- Constellation Software on Track for Record M&A Year Despite 3Q Hiccup -- Market Talk
- BUZZ-TransDigm shares fall as its annual earnings forecast trails market expectations
- Charles River Capital Cuts BrasilAgro Stake to 9.98%, Below 10% Threshold
- IsoEnergy confirms high-grade uranium 500 meters east of Hurricane deposit
- Simpar Board Raises No Objections to Q3 2026 Financial Statements
- TSMC approves investment of up to $500 million in OpenAI preferred shares
- Djasa Ubersakti Says Debt Restructuring Covers Rp 132.91 Billion in Claims
- Sionna Therapeutics Presents Plans for Phase 2 Trial of Cystic Fibrosis Drug Combination
- TSMC approves about $40.9 billion capital expenditure budget for long-term capacity planning
- Anthropic may issue up to $42 billion in notes to Broadcom
- CalciMedica Q3 net loss narrows 78% to $1.7 million
- Aterra Metals cuts Totora inferred resource estimate by 6.1%
- FERGUSON ENTERPRISES INC. <FERG.N>: DEUTSCHE BANK RAISES TARGET PRICE TO $273 FROM $235
- New Age Metals Advances Till Sampling at Sentinel Gold-Antimony Project in Newfoundland
- Cellectar BioSciences Q3 net loss widens 79% to $7.97 million
- Kustom Entertainment swings to Q3 net income of $2.35 million
- Evergold drilling extends Golden Lion mineralization 80 meters northwest
- Altcoin Liquidity Is Quietly Shifting: 5 Cryptos That Could Benefit From the Next Market Rotation
- SELKIRK COPPER MINES INC <SCMI.V>: HAYWOOD SECURITIES INITIATES COVERAGE WITH BUY RATING; TARGET PRICE C$2
- FORTUNE BRANDS INNOVATIONS, INC. <FBIN.N>: DEUTSCHE BANK RAISES TARGET PRICE TO $48 FROM $41
- Cellectar Biosciences 3Q Loss $7.97M >CLRB
- Kustom Entertainment 3Q Rev $2.7M >KUST
- Kustom Entertainment 3Q EPS $4.51 >KUST
- Janus Henderson Investors UK Raises Elmos Semiconductor Voting Rights to 3.02% From 2.94%
- Absa Group Announces Interest Payments Due Nov. 16-20, 2026
- Cullinan Therapeutics Q3 net loss narrows to $49.4 million
- Eneco Energy Launches S$ 5 Million Share Buyback Program
- PRAXIS PRECISION MEDICINES, INC. : DEUTSCHE BANK RAISES TARGET PRICE TO $483 FROM $475
- Legend Biotech Names Ingrid Zhang CEO
- Bitdeer Q3 2026 net loss widens year over year to USD 125.5 million; Q3 2026 revenue rises 89% to USD 320.7 million
- WHITE GOLD CORP. <WGO.V>: STIFEL INITIATES COVERAGE WITH SPECULATIVE BUY RATING; TARGET PRICE C$3.45
- COGNEX CORPORATION <CGNX.O>: DAIWA CAPITAL MARKETS CUTS TARGET PRICE TO $56 FROM $76
- Humacyte Q3 net loss narrows 11% year over year to $15.54 million
- SAREPTA THERAPEUTICS, INC. <SRPT.O>: DEUTSCHE BANK RAISES TO HOLD FROM SELL; RAISES TARGET PRICE TO $18 FROM $14
- PepGen Q3 net loss widens 8% to $19.39 million
- Adtran Networks Q3 2026 operating profit more than triples year on year to EUR 9.13 million
- ONGWE MINERALS INC <OGW.V>: STIFEL INITIATES COVERAGE WITH SPECULATIVE BUY RATING; TARGET PRICE C$2.80
- ZYMEWORKS INC. <ZYME.O>: TRUIST SECURITIES RAISES TARGET PRICE TO $36 FROM $35
- Scholar Rock Holding 3Q Rev $570,000 >SRRK
- ZETA GLOBAL HOLDINGS CORP. <ZETA.N>: TRUIST SECURITIES RAISES TARGET PRICE TO $40 FROM $38
- Founder Group swings to net profit of RM 791,785 for six months ended June 30, 2026
- MOGOTES METALS INC <MOG.V>: STIFEL INITIATES COVERAGE WITH SPECULATIVE BUY RATING; TARGET PRICE C$0.58
- Olema Pharmaceuticals Names Jason O'Byrne Chief Financial Officer
- Harvard Bioscience Q3 net loss more than doubles to $2.6 million; Q3 revenue rises 8% to $22.2 million
- IHS Holding Announces Availability of Third-Quarter 2026 Earnings Release
- Palomino Laboratories Participates in Stifel Deep Tech Forum
- HKFoods takes full ownership of salad maker Mäkitalon Maistuvat
- TOAST, INC. <TOST.N>: TRUIST SECURITIES RAISES TARGET PRICE TO $40 FROM $38
- REALTY INCOME CORPORATION <O.N>: TRUIST SECURITIES RAISES TARGET PRICE TO $63 FROM $60
- Gilat Q3 2026 non-GAAP net income rises 21% year over year to $14.29 million
- Urban One 3Q Loss/Shr $26.39 >UONE
- Ionis Pharmaceuticals Participates in Fireside Chats at Four Investor Conferences
- Ovid Therapeutics Q3 2026 net loss widens 70% to $20.8 million
- BioNTech to Buy FDA Priority Review Voucher From Scholar Rock for $205 Million
- Gold X2 Intersects 258.4 Meters of 0.97 g/t Gold Below Current Pit Shell at Moss Project
- LENSAR Q3 2026 net loss widens 27% year over year to $4.72 million
- Upstream Bio Q3 net loss widens 22% to $41.19 million
- Founder Group management commentary attributes first-half 2026 return to net profit to higher project revenue
- ARRIVENT BIOPHARMA, INC. : TRUIST SECURITIES RAISES TARGET PRICE TO $24 FROM $21
- Quarterhill management commentary cites acquisition-related charges as driver of higher Q3 2026 operating expenses
- Humacyte 3Q Loss/Shr 6c >HUMA
- Quarterhill 3Q Rev $43.2M >QTRHF
- IsoEnergy Has Agreed to Acquire 13,642,775 Shares of Premier Amer Uranium >ISOU
- Excalibur Metals hires Precision GeoSurveys for airborne survey at Bellehelen silver-gold project
- Sweet Earth Holdings Changes Name to Vesalius Longevity Labs
- TSMC October Revenue Rises 59.7% Year Over Year to NT$ 586.89 Billion
- 908 Devices forecasts 2026 revenue of $68.5 million to $70 million
- Ethan Allen Names Stefanie Tsen Ward Interim CEO
- Opus Genetics Q3 net loss more than doubles to $46.5 million
- Ocugen licenses OCU400 to Celairis for Australia, New Zealand and ASEAN markets
- Quarterhill Q3 2026 net loss more than triples year over year to USD 16.46 million; Q3 2026 revenue rises 9% year over year to USD 43.2 million
- Gain Therapeutics 3Q Loss $3.16M >GANX
- IsoEnergy Increases Strategic Holding in Premier Amer Uranium Inc.
- Ovid Therapeutics 3Q Research and Development Expenses $15.7M >OVID
- Gain Therapeutics 3Q Loss/Shr 7c >GANX
- Upstream Bio 3Q Rev $395,000 >UPB
- Sionna Therapeutics Q3 2026 net loss widens 60% to $32.42 million
- Millennial Potash intersects 132 meters of cumulative potash mineralization at Banio project
- Nurix Therapeutics Participates in Fireside Chats at Three Investor Conferences
- GreenLight Metals Intersects 1.20% Copper, 1.33 g/t Gold Over 30.62 Meters at Bend Project
- LINCOLN EDUCATIONAL SERVICES CORP <LINC.O>: ROSENBLATT SECURITIES CUTS TARGET PRICE TO $40 FROM $50
- Chicago Atlantic Real Est 3Q EPS 25c >REFI
- PepGen 3Q Loss $19.4M >PEPG
- PepGen 3Q Loss/Shr 28c >PEPG
- FactSet Research Backs FY27 Adjusted Operating Margin View of 34.75%-35.25% >FDS
- FactSet Research Backs FY27 View of Organic ASV Growth 5%-6.5% >FDS
- FactSet Research Backs FY27 View of EPS $17.00-EPS $17.50 >FDS
- ENOVA ANNOUNCES NEW $500 MILLION SHARE REPURCHASE PROGRAM >ENVA
- Harvard Bioscience 3Q Rev $22.2M >HBIO
- Scholar Rock Holding 3Q Loss/Shr 81c >SRRK
- --Northland Securities Downgrades Vistance Networks to Market Perform From Outperform
- Top Premarket Gainers
- --JPMorgan Upgrades Orion to Neutral From Underweight
- -- Earnings Flash (CGEM) Cullinan Therapeutics, Inc. Reports Q3 Loss of $0.74 per Share
- --Earnings Flash (CGEM) Cullinan Therapeutics Posts Q3 Net Loss $0.74 a Share, vs. FactSet Est of $0.86 Loss
- Torex Resources to Start Trading on the New York Stock Exchange
- --Earnings Flash (IMTX) Immatics Posts Q3 Net Loss 0.50 Euros a Share
